Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

<p>Supplementary Figure 2 shows the distribution of individual total (combined adenomatous and serrated polyp) colorectal polyp counts according to seAFOod trial treatment allocation by factorial margins and ALOX SNP genotypes.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	John R. Davies (17314989) (author)
مؤلفون آخرون:	Tracey Mell (17314992) (author), Harriett Fuller (17314995) (author), Mark Harland (17314998) (author), Rasha N.M. Saleh (17315001) (author), Amanda D. Race (17315004) (author), Colin J. Rees (17315007) (author), Louise C. Brown (17315010) (author), Paul M. Loadman (17315013) (author), Amy Downing (17315016) (author), Anne Marie Minihane (17315019) (author), Elizabeth A. Williams (17315022) (author), Mark A. Hull (17315025) (author)
منشور في:	2025
الموضوعات:	Cancer Clinical Research and Trials Cancer Prevention Clinical prevention studies Pre-neoplasia Clinical Trial Results Phase III clinical trials Gastrointestinal Cancers Colorectal cancer
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Supplementary Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
حسب: John R. Davies (17314989)
منشور في: (2025)

Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
حسب: John R. Davies (17314989)
منشور في: (2025)

Supplementary Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
حسب: John R. Davies (17314989)
منشور في: (2025)

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
حسب: Yansong Lin (16374208)
منشور في: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
حسب: Lenka Stolarova (16547259)
منشور في: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
حسب: Lenka Stolarova (16547259)
منشور في: (2025)

Table S3 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
حسب: Lenka Stolarova (16547259)
منشور في: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
حسب: Axel Stenmark Tullberg (15029928)
منشور في: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
حسب: Roger Li (17078665)
منشور في: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
حسب: Chong Kin Liam (15331321)
منشور في: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
حسب: Chong Kin Liam (15331321)
منشور في: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
حسب: Chong Kin Liam (15331321)
منشور في: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
حسب: Chong Kin Liam (15331321)
منشور في: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
حسب: Amir T. Fathi (15313195)
منشور في: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
حسب: Amir T. Fathi (15313195)
منشور في: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
حسب: Zachary Quinn (15052893)
منشور في: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
حسب: Srivandana Akshintala (16610490)
منشور في: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
حسب: Srivandana Akshintala (16610490)
منشور في: (2025)

Supplementary Table 1 from Bacterial Vaginosis Decreases the Risk of Cervical Cytological Abnormalities
حسب: Tengfei Long (15105736)
منشور في: (2025)

Supplementary Table 2 from Bacterial Vaginosis Decreases the Risk of Cervical Cytological Abnormalities
حسب: Tengfei Long (15105736)
منشور في: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
حسب: Raphaël Leman (17314506)
منشور في: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
حسب: Raphaël Leman (17314506)
منشور في: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
حسب: Raphaël Leman (17314506)
منشور في: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
حسب: Raphaël Leman (17314506)
منشور في: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
حسب: Raphaël Leman (17314506)
منشور في: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
حسب: Raphaël Leman (17314506)
منشور في: (2025)

Supplementary Table S1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
حسب: Nan Deng (17314330)
منشور في: (2025)

Supplementary Table S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
حسب: Nan Deng (17314330)
منشور في: (2025)

Supplementary Table S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
حسب: Nan Deng (17314330)
منشور في: (2025)

Supplementary Table S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
حسب: Nan Deng (17314330)
منشور في: (2025)

Supplementary Table S5 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
حسب: Nan Deng (17314330)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_un36f5dra5jpeuejvnae401oi3